Resistance to targeted therapies in breast cancer
We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast can...
Saved in:
Other Authors | |
---|---|
Format | Electronic eBook |
Language | English |
Published |
Cham, Switzerland :
Springer,
[2017]
|
Series | Resistance to targeted anti-cancer therapeutics ;
v. 16. |
Subjects | |
Online Access | Plný text |
Cover
Loading…